Compare NECB & MOBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NECB | MOBI |
|---|---|---|
| Founded | 1934 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.0M | 383.0M |
| IPO Year | 2021 | 2026 |
| Metric | NECB | MOBI |
|---|---|---|
| Price | $27.77 | $8.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $30.00 | $17.75 |
| AVG Volume (30 Days) | 33.1K | ★ 263.1K |
| Earning Date | 10-26-2026 | 11-12-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.26 | $71.88 |
| Revenue Next Year | $18.16 | $43.02 |
| P/E Ratio | $18.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.27 | $8.29 |
| 52 Week High | $28.94 | $15.19 |
| Indicator | NECB | MOBI |
|---|---|---|
| Relative Strength Index (RSI) | 61.44 | 38.05 |
| Support Level | $25.83 | $8.45 |
| Resistance Level | $28.94 | $9.85 |
| Average True Range (ATR) | 0.63 | 0.68 |
| MACD | 0.10 | -0.01 |
| Stochastic Oscillator | 92.36 | 21.79 |
NorthEast Community Bancorp Inc operates as a community-oriented financial institution. It is principally engaged in the business of attracting deposits and investing those funds into mortgage and commercial loans. It conducts activities throughout the Northeastern United States, including New York, Massachusetts, New Jersey, and Connecticut. The company offers a comprehensive line of banking products and services, including mobile banking as well as commercial real estate loans, commercial construction financing, lines of credit, and term loans. It also offers investment advisory and financial planning services.
Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The company develops, markets and sells devices for the treatment of medical conditions. Its flagship device is the Vivistim Paired Vagus Nerve Stimulation system, which is used to support motor function rehabilitation in patients with chronic ischemic stroke. The company generates all of its revenue from the sale of the Vivistim System to customers, mainly primary and comprehensive stroke centers, in the United States.